Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas

Table 1 Clinicalpathological parameters of BTC case series

Sample	Sex	Age	Origin	TNM *	Grade
1	M	75	GBC	T3N0M0	2
2	M	72	ICC	T3N1M0	3
3	F	48	ICC	T3N0M0	3
4	M	46	ECC	T3N1M0	3
5	M	70	ECC	T3N1M0	3
6	M	74	ECC	T3N1M0	3
7	M	69	ICC	TxN1M1	3
8	M	47	ICC	TxN1M1	2
9	F	50	ICC	T1N0M0	2
10	M	67	ICC	T3N0M0	2
11	M	50	ICC	T2NxM0	3
12	F	54	GBC	TxN1M1	2
13	M	73	ECC	T3N0M0	3
14	M	64	ECC	T3N0M0	2
15	M	53	ECC	T3N0M0	2
16	M	63	ECC	T4N0M0	2
17	F	57	ECC	T3N2M0	3
18	M	74	ECC	T2N1M0	3
19	M	69	ECC	T2N0M0	1
20	M	68	GBC	T2N0M0	2
21	M	66	ICC	T3N1M0	3
22	M	64	ECC	T2N0M0	3
23	F	75	GBC	T3NxM0	3
24	M	72	ECC	T3N1M0	2
25	F	66	ICC	T4N1M0	3
26	F	70	ECC	TxN1M0	1
27	F	71	GBC	T2N1M0	3
28	F	78	GBC	T2NxM0	3
29	F	60	ECC	T3N1M0	3
30	F	51	GBC	T3N1M0	2
31	F	41	ICC	NA	3
32	F	69	GBC	T2N1M0	3
33	F	84	GBC	T2NxM0	3
34	M	83	GBC	T2NxM0	3
35	M	56	GBC	T2NxM0	3
36	F	61	ICC	TxNxM1	3
37	F	72	ICC	TxNxM0	3
38	F	69	GBC	T3N0M0	3
39	M	52	ICC	TxNxM0	3
40	M	67	ECC	TxNxM0	2
41	M	66	ICC	T3NxM0	3
42	F	53	ECC	T3N1M0	2
43	M	68	ECC	TxNxM0	3
44	F	73	ECC	T2N0M0	2
45	F	55	GBC	T4N1M0	3
46	M	53	ICC	TxNxM1	3
47	M	66	ICC	T3NxM0	3
48	F	53	ICC	TxNxM0	3
49	M	67	ECC	T4N1M0	2

ICC: Intrahepatic cholangiocarcinoma; ECC: Extrahepatic cholangiocarcinoma; GBC: Gallbladder carcinoma, * TNM staging (see ref. [30])

ISSN: 1471-2407